trial

Ziprasidone vs Standard Therapy for Agitated Patients in the ED

NCTId NCT00786318
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Withdrawn
Enrollment 0 (actual)
Sponsored by George Washington University
Primary completion 2011-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Withdrawn
Enrollment
0 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2008-09
Primary completion
2011-07
Eligibility
ALL · 18 Years · 100 Years

Interventions & indications

Drugs
ZiprasidoneStandard therapy

Sponsors

George Washington UniversityLead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Collaborator

Sites

1 total
Washington D.C., United States

Facts & assertions

4 sourced
Enrollment
0
Phase
PHASE4
Primary Completion Date
2011-07
Status
WITHDRAWN
relationships
The graph out of here
drug
Ziprasidone
drug
Standard therapy
drug
lead_sponsor
George Washington University
company
collaborator
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
company
indication
Psychomotor Agitation
indication
Psychosis
indication
Psychotic Disorders
indication